TrialCancer science2023

Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.

Takayuki Yoshino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.